. Author manuscript; available in PMC: 2021 Jul 1.

Published in final edited form as: Nat Rev Clin Oncol. 2020 Jun 8;17(9):569–587. doi: 10.1038/s41571-020-0377-z

Table 2.

Targeted therapy in MET exon 14-altered lung cancers

Inhibitor Type	Type Ia	Type Ib

Drug	Crizotinib⁷⁷	Capmatinib¹¹³	Tepotinib¹⁴⁰	Savolitinib²⁰⁷

Objective response rate (ORR)	32% (95% CI 21–45) n=21/65			52% (95% CI NR) n=17/31

ORR by treatment
Naïve (no systemic therapy) Pre-treated (no prior c-MET therapy)		68% (95% CI 48–84) n=19/28 41% (95% CI 29–53) n=28/69	44% (95% CI 22–69) n=8/18 45% (95% CI 28–64) n=15/33

ORR by mutation type
Insertion/deletion Point Mutation	0% (95% CI NR) n=0/4 36% (95% CI NR) n=12/33	NR	NR	43% (95% CI NR) n=6/14 59% (95% CI NR) n=10/17

ORR by splice site
Splice acceptor Splice donor	31% (95% NR) n=5/16 32% (95% CI NR¹⁵⁰) n=12/37	NR	NR	42% (95% CI NR) n=5/12 58% (95% CI NR) n=11/19

ORR by MET amplification
Concurrently amplified Wild-type	0% (95% CI NR) n=0/2 NR (95% CI NR) n=NR	NR	NR	100% (95% CI NR) n=5/5 35% (95% CI NR) n=8/23

Median progression-free survival	7.3 months (95% CI 5.4–9.1)		12.3 months (95% CI 6.3-NR)	NR

Median progression-free survival
Naïve (no systemic therapy) Pre-treated (no prior MET TKI)		9.7 months (95% CI 5.5–13.9) 5.4 months (95% CI 4.1–7.0)

NR, not reported